However, the effect of raloxifene was marginally insignificant due to insufficient sample size (HR, 0.50; 95% CI, 0.24–1.04; P , 0.064), and there was no significant association between tolterodine and breast cancer risk (HR, 1.02; 95% CI, 0.92–1.13; P , 0.711).
← all excerpts
Identifying actionable druggable targets for breast cancer: Mendelian randomization and population-based analyses.
1
—
—